JVIDÊÓƵ

Viral vectors have become a crucial component in cell and gene therapy research. These microscopic delivery systems are revolutionizing medicine by delivering therapeutic genes directly into patient cells, offering hope for countless individuals suffering from genetic disorders. While viral vectors have proven to be a valuable tool in the early stages of drug development, scientists face several challenges as they work on taking new and innovative discoveries to market.

The history of viral vectors in gene therapy spans several decades, dating back to the 1960s. Viral vector technology has experienced multiple cycles of progress and challenges over this time. While there were promising early developments, the field faced significant setbacks in the 1990s when safety concerns emerged during clinical trials. After a period of reassessment, recent years have seen renewed progress, though important challenges remain. Durability can vary widely depending on the serotype, dosage, delivery system and targeted location. Efficacy and expression have also shown to decline over time. While significant advances have been made to the safety of viral vectors, research continues toward developing longer lasting treatments.

Adeno-associated viruses (AAVs), which were the first type of genetic vehicles to be delivered in the 1960s, have shown promising results in clinical trials in the early 2010s with their more recent versions. These vectors have a lower immune response and can carry large genetic payloads, making them a promising tool for future cell and gene therapy solutions.

The production of viral vectors presents researchers with unique challenges that are not experienced in traditional pharma such as cost of production (one batch can cost millions to produce), specialized labor and technologies, limited availability of test methods, and higher scrutiny to ensure safety and efficacy in every batch. Given the history of gene therapies on clinical trial resulting in cancer and even death, safety is the number one most concern. The need to show clearance of unwanted contamination that impact the safety and efficacy of vectors, ultimately lead to delays in product development and hinder their potential to improve patient outcomes. In this blog, we will explore the impact of contaminants on viral vector production and how enhancing production pipelines can help expedite product development and improve efficacy.

The impact of contaminants in viral vector production

Contaminants are any unwanted substances that can enter the production process and affect the safety quality of the final product. In the case of viral vectors, contaminants can arise from various sources, such as raw materials and ancillary reagents used in manufacturing, the cells that produce the vectors, and non-productive forms of the vector such as empty or degraded vectors. These contaminants can compromise the integrity of the viral vector, reducing its potency and potentially causing adverse effects in patients. Therefore, it is critical to identify and eliminate contaminants to ensure the safety and efficacy of viral vectors.

“…It is critical to identify and eliminate contaminants to ensure the safety and efficacy of viral vectors.”

A primary source of contaminants is unwanted DNA contamination from various steps in the manufacturing process. This can include plasmid DNA from the transfection process, residual double-stranded DNA from the mammalian host cells, and the genetic material to be delivered (single-strand DNA), which sometimes gets packaged only partially. All of these DNA contaminants need to be cleared to varying degrees, with partially packaged vectors being of somewhat less concern. These materials can potentially introduce harmful genetic material to the patient that could risk safety and efficacy. In addition to utilizing effective packaging and post-production workflows to ensure high-quality product, quality control testing of all viral vectors is critical to ensure purity.

The presence of adventitious agents, which are microorganisms that can contaminate the production process, is a potential source of contamination in viral vectors. These agents can originate from the raw materials used in production, such as cell lines and culture media, or from the general environment they are subjected to. The presence of adventitious agents can lead to batch failures, resulting in delays in product development and significant financial losses. Therefore, it is essential to implement strict quality control measures to prevent the introduction of adventitious agents into the production process.

Streamlining the development process

Lengthy and complex processes are another significant challenge in gene and cell therapies. Research and development of therapies can often take 5-10 years to reach clinical trials. To accelerate the progress of these life-saving treatments, it is critical to streamline the discovery and development process to accelerate moving through the preclinical development workflow by considering Chemistry, Manufacturing and Controls (CMC) practices as early as during lab scale production.

Streamlining the development process involves optimizing and simplifying the steps involved in bringing a gene therapy from concept to market. This includes everything from research and development to manufacturing and regulatory approval. By streamlining processes across the extended workflow, researchers can save time, resources, money, and ultimately, lives.

“By streamlining processes across the extended workflow, researchers can save time, resources, money, and ultimately, lives.”

A key approach to streamlining the development process is using advanced technologies and techniques. For example, the use of automation and robotics in the laboratory can increase efficiency and reduce the time it takes to complete experiments. Additionally, the use of high-throughput screening methods and bioassays can help identify potential therapies more quickly and accurately.

Another important aspect of streamlining the development process is collaboration and communication between different stakeholders. This includes researchers, clinicians, vendors, manufacturers, and regulatory bodies. By working together and sharing knowledge and resources, the development process can be accelerated, and potential roadblocks can be identified and addressed more efficiently and much earlier in the process. In addition to streamlining the development process, it is also crucial to shorten the preclinical development workflow. This refers to the steps involved in testing and evaluating a therapy before it can be formally administered in human clinical trials. This process can often take several years, which can be a major barrier to bringing life-saving treatments to patients in need.

One way to shorten the preclinical development workflow is by using AI predictive models and simulations. These innovative tools can help researchers identify potential safety and efficacy issues early on, allowing researchers to make adjustments that help avoid delays in the development process. Additionally, therapeutic enzyme and protein analysis can also help researchers track the progress of a therapy and make more informed decisions about its potential for success.

Shortening the preclinical development workflow also involves efficient and effective data management. With the vast amount of data generated during the development process, it is crucial to have systems in place to organize, analyze, and interpret this data. This can help researchers make more informed decisions and identify potential issues more quickly in preparation for preclinical and clinical regulatory submissions.

During a recent webinar titled , JVIDÊÓƵ partnered with Contract Pharma to shed light on challenges researchers face when testing the safety of cell and gene therapy solutions.

If you are a manufacturer of cell and gene therapy products, you are certainly aware of the critical role mycoplasma testing plays on the quality and safety of the therapeutic product. USP guidelines require that manufacturers of biological products, and the related materials used to generate those products, are tested for mycoplasma. Current regulations cite testing that requires a minimum total incubation time of at least 14-28 days, which can both create delays in commercialization and jeopardize the product’s viability.

Advances in PCR technology now offer Rapid Mycoplasma testing options that deliver results in as little as a day. In addition to the speed of testing being reduced, the volume of product needed to conduct the testing is also much less. For organizations fighting to achieve a first-to-market advantage, saving time and enhancing efficiency are critical throughout the development process.

Conclusion

Viral vectors play a crucial role in supporting cell and gene therapy research. They are efficient, targeted, and versatile tools for delivering genetic material to cells. While there are still challenges to overcome, advancements in viral vector research are continuously being made, offering new possibilities for treating a wide range of diseases and disorders.

The impact of contaminants on viral vector production cannot be underestimated. Contaminants can significantly affect the efficacy of these vectors, leading to delays in product development and hindering their potential to improve patient outcomes and further set back gene therapy as a potential cure for patients with devastating diseases. With a focus on eliminating contaminants and addressing production challenges, the use of viral vectors in biotechnology applications can continue to revolutionize the field of medicine and offer hope for patients in need.

For more information on ensuring quality and safety in your viral vector production processes, explore JVIDÊÓƵ's comprehensive testing and analytical services designed specifically for cell and gene therapy developers.

Ready to start the conversation? Get in touch with an expert today.